NY-ESTÉE-LAUDER
14.9.2022 22:31:34 CEST | Business Wire | Press release
Today, Executive Chairman William P. Lauder and President and Chief Executive Officer Fabrizio Freda of The Estée Lauder Companies Inc. (NYSE:EL) (“ELC”) announced an organizational evolution across its brand portfolio to strategically position the company for long-term, sustainable growth in a fast-paced evolving global landscape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005700/en/
Jane Hertzmark Hudis, Executive Group President, The Estée Lauder Companies (Photo: Business Wire)
Effective September 1, 2022, the company’s brand portfolio evolved into two brand clusters led by Jane Hertzmark Hudis, Executive Group President, and Stéphane de La Faverie, who has been promoted to Executive Group President. This new brand leadership structure is designed to ensure continued portfolio-wide alignment, enabling the business to focus on the greatest areas of opportunity. Jane and Stéphane will continue to report directly to Fabrizio Freda.
“This evolution further positions The Estée Lauder Companies’ brands to win with consumers in a complex and continuously changing beauty landscape, while elevating our internal talent bench and organizational planning to position us well to deliver on the company’s long-term strategy with agility,” said Fabrizio Freda. “The strength of our portfolio reflects the strength of our leadership team, and this evolution leverages the track record and high potential of each leader to take our business to even greater heights in the future.”
Building upon their enterprise-wide leadership responsibilities, Jane and Stéphane, in partnership with the Brand Presidents, will oversee their brands’ businesses, equity and innovation, continuing to work in close alignment with all internal functions and regions. Additionally, they will work closely with brand and value chain leaders to drive the strategy and growth plans for the company’s product categories and key subcategories.
“We have been and will continue to be a brand-led company. This exciting update to the organization will further enable our brands’ industry leadership,” said William P. Lauder. “Leveraging ELC’s internal talent pipeline globally underscores our commitment to create new professional development and career advancement opportunities for the next generation of leaders across our organization.”
This organizational evolution aligns with ELC’s forward-looking corporate strategy and Compass to accelerate the company’s ability to deliver now while simultaneously preparing for the future. The company’s top brand leaders are organizationally aligned in a management structure designed to promote cross-brand synergies and advance development at multiple levels of the organization. In line with the company’s internal talent vision, this announcement also includes the appointment of several leaders to elevated brand roles within the clusters of Jane and Stéphane.
Executive Group President Jane Hertzmark Hudis will continue leading one of the company’s brand clusters, with a portfolio of brands that includes: La Mer and Bobbi Brown; TOM FORD BEAUTY; M·A·C; Clinique and Origins; Aveda; Bumble and bumble; and Dr.Jart+. Jane will also continue her enterprise-wide executive leadership of skin care and hair care, which are important growth-driving categories for our company. All the current brand leaders will remain the same, with the exception of Sandra Main taking direct responsibility of La Mer. In addition, Jane will continue as an executive sponsor for key strategic enterprise-wide priorities, including initiatives focused on marketing excellence and winning with Chinese consumers.
As one of the most accomplished, visionary executives in prestige and luxury beauty, Jane has a proven track record of leading, building, and transforming global brands to achieve outstanding broad-based growth. Jane will leverage her tenured expertise, including her vast knowledge of China, luxury beauty, and consumer-centric local relevance, to further enable her brand portfolio to win across categories, regions, and channels.
Jane is a passionate advocate of leadership development, mentorship, and women’s advancement. In addition to her enterprise-wide responsibilities at the company, Jane co-founded The Estée Lauder Companies’ Women’s Leadership Network (“WLN”) in 2017 to inspire and engage women across the organization, helping them become exceptional leaders and mentors. Under Jane’s co-executive sponsorship, WLN has become the company’s largest employee resource group with a presence in every region.
As Executive Group President, Stéphane de La Faverie will continue to lead one of the company’s brand clusters including Estée Lauder and AERIN Beauty; Jo Malone London; Le Labo; KILIAN PARIS, Editions de Parfums Frederic Malle, Darphin Paris and LAB Series; and DECIEM (The Ordinary, NIOD, and Avestan). Additionally, Stéphane will add ELC’s California-based brands to his portfolio – Too Faced; Smashbox and GLAMGLOW – expanding his category leadership to now include makeup, in addition to fragrance and subcategories of home, bath and body, and men’s skin care and grooming. With the exception of Estée Lauder, all the leaders of the brands now in Stéphane’s portfolio remain the same. Stéphane will also continue to drive integrated planning and end-to-end business operations enterprise-wide.
Stéphane’s promotion to Executive Group President reflects his outstanding track record of building successful global brands and his deep expertise across categories and channels, helping build fragrance as a powerful engine of growth for the company, and leading the Estée Lauder brand to be one of the world’s most beloved prestige beauty brands.
Stéphane’s strength as an inclusive and empathic leader, and his ability to balance emotional inspiration, authenticity and strategic insights to drive long-term, sustainable growth, have helped him successfully build his portfolio of brands and nurture a winning leadership team.
Additional Brand Leadership Updates
- Justin Boxford has been appointed Global Brand President, Estée Lauder. He will report to Stéphane. A separate announcement on Justin’s appointment will be shared in the coming days.
- Sandra Main, Global Brand President, La Mer and Bobbi Brown, will assume direct leadership of La Mer and will oversee Bobbi Brown until a new leader is named. Sandra will continue reporting to Jane.
- Michelle Freyre has been promoted to Global Brand President, Clinique and Origins, expanding her brand oversight. Michelle will report to Jane.
- Amber Garrison, who assumed the role of Global Brand President, Origins in July 2022, will continue as a member of Jane’s leadership team and report to Michelle Freyre.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, LAB Series, Origins, M·A·C, La Mer, Bobbi Brown, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD BEAUTY, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
ELC-L
ELC-C
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005700/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
